Conversely, enhancement in MCF-7 and MDA-MB-231 tumor cell growth resulting from combined low dose treatment of γ-tocotrienol with PPARγ agonists was associated with an increase in PPARγ, PPRE mediated reporter activity, and RXR, a decrease in PPARγ coactivator expression, and a corresponding restoration in EGF-dependent PI3K/Akt mitogenic-signaling as compared to their vehicle-treated control group. The gene discussed is EGF; the disease is neoplasm.